Neural Stem Cells not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke”In the company’s words, NCT04631406 on ClinicalTrials.gov
- Tested for
- Ischemic Stroke
- Main trialPhase 1/2
- “Evaluation of the safety and tolerability of escalating doses of NR1 administered intracerebrally at a single time-point post-injury to subjects with chronic ISS with or without cortical stroke.”In the company’s words, NCT04631406 on ClinicalTrials.gov
Other drugs for Ischemic Stroke
- Neuroncell-EXCytopeutics Sdn. Bhd. · Phase 2/3
- DM199DiaMedica Therapeutics Inc · Phase 2/3
- SP-8203Shin Poong Pharmaceutical Co. Ltd. · Phase 3
- SHPL-49Shanghai Hutchison Pharmaceuticals Limited · Phase 3
- RhTNK-tPACSPC · Phase 3
- SovateltidePharmazz, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 12 Aug 2025 | A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026